| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| NEN Life Sciences, Inc. |
| 549 Albany Street, Boston, MA 02118 * (617) 482-9595 |
| Business Description | The company is a leading global provider of value-added research products, proprietary technologies and services for the life science industry. |
|
Filing Information IPO has been | |||
| To Trade As | NENL (NASNTL) | Industry | Manufacturing (SIC 3679) |
| Type of Stock Offered | Common Shares | Filing Date | 4/7/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $80,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| CS First Boston | Lead Manager | (212) 325-2000 |
| ING Baring Furman Selz | Co-manager | (212) 309-8200 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | 101.600 | 95.100 | 92.215 | 94.784 | 103.854 | - | - |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | 4.600 | 7.800 | -4.369 | 0.898 | 16.969 | - | - |
| E.P.S | - | - | - | 0.060 | 1.060 | - | - |
| Revenue Growth (%) | -6.40 | -3.03 | 2.79 | 9.569 | - | ||
| Net Income Growth (%) | 69.57 | - | - | 1,789.64 | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | 4.53 | 8.20 | - | 0.95 | 16.34 | - | - |
| Cash Flow - Oper. | 15.14 | - | - | ||||
| Cash Flow - Inv. | -7.58 | - | - | ||||
| Cash Flow - Fin. | -8.18 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 99.44 | Current Assets | 33.56 | Current Ratio | 1.28 |
| Total Liab. | 74.32 | Current Liab. | 26.32 | Debt Ratio | 74.74% |
| Total Equity | 25.12 | Working Cap. | 7.24 | Debt to Equity Ratio | 2.96 |
| Cash | 0.89 | Return on Assets | 17.06% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to repay debt, and for working capital, capital expenditures, including technology licenses and acquisitions, and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Latham & Watkins |
| Bank's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Genstar Capital LLC | 85.50 | |
| StarGen II LLC | 1.70 | |
| Note: represents ownership of 5% or more prior to the offering. | ||